New Arrivals/Restock

History of Novartis

flash sale iconLimited Time Sale
Until the end
00
56
31

$12.76 cheaper than the new price!!

Free shipping for purchases over $99 ( Details )
Free cash-on-delivery fees for purchases over $99
Please note that the sales price and tax displayed may differ between online and in-store. Also, the product may be out of stock in-store.
New  $25.52
quantity

Product details

Management number 201904590 Release Date 2025/10/08 List Price $12.76 Model Number 201904590
Category


Novartis is a Swiss multinational pharmaceutical company that traces its history back to the first dye factories in Basel in the early 19th century. This second edition of the company's history covers early exports and expansion abroad, the unparalleled upsurge of the chemical industry in Basel during the First World War, and the emergence of pharmaceuticals in the interwar years. The 1950s and 60s saw an economic boom, the merger of CIBA and Geigy, the numerous diversifications in the 1970s and 80s, the merger of Ciba and Sandoz to found Novartis, and the first 25 years of Novartis, which have included innovations in pharmaceuticals and medicine and game-changing technologies such as the modification of T-cells.

\n Format: Hardback
\n Length: 208 pages
\n Publication date: 30 September 2021
\n Publisher: Profile Books Ltd
\n


One of the world's leading pharmaceutical companies, the Swiss multinational Novartis, traces its history and that of its predecessor companies back to the first dye factories in Basel in the early 19th century. This second edition of the company's history covers early exports and expansion abroad, the unparalleled upsurge of the chemical industry in Basel during the First World War, and then the emergence of pharmaceuticals in the interwar years. The enormous challenges of the Second World War were followed by an economic boom in the 1950s and 60s, the merger of CIBA and Geigy, the numerous diversifications in the 1970s and 80s, the merger of Ciba and Sandoz to found Novartis, and finally the first 25 years of Novartis. Those 25 years have included innovations in pharmaceuticals and medicine, and game-changing technologies such as the modification of T-cells. In addition to the running text, fifteen thematic articles outline the company's widely different innovations: from CIBA's early hormone preparations to the outstanding graphic design of Geigy Design, from revolutionary drugs like Sandimmune or Gleevec right through to the Novartis Campus project.

Novartis, a Swiss multinational pharmaceutical company, boasts a rich history that traces its roots back to the early 19th century when Basel became the hub of dye factories. This second edition of Novartis' history delves into the early stages of the company's growth, including its expansion abroad, the remarkable surge of the chemical industry during World War I, and the subsequent emergence of pharmaceuticals in the interwar years. The challenges of World War II were followed by a period of economic prosperity in the 1950s and 60s, marked by significant mergers and diversification efforts. One of the pivotal moments in Novartis' history was the merger of CIBA and Geigy in 1996, which created a global pharmaceutical powerhouse. Over the years, Novartis continued to innovate, introducing groundbreaking technologies and medications that have transformed healthcare. One notable achievement was the development of the drug Gleevec, which has revolutionized the treatment of leukemia. In addition to its pharmaceutical endeavors, Novartis has made significant contributions to medical research and education. The company operates research facilities around the world and collaborates with academic institutions to advance scientific knowledge and find new treatments for diseases. Novartis also sponsors various programs aimed at improving access to healthcare in developing countries.

Throughout its history, Novartis has maintained a strong commitment to corporate responsibility and sustainability. The company has implemented various initiatives to reduce its environmental footprint, promote social well-being, and support communities. For example, Novartis has invested in renewable energy projects and implemented waste management systems that prioritize recycling and waste reduction. Novartis has also been recognized for its efforts in promoting diversity and inclusion within the workplace. The company has established diversity committees and programs to ensure that all employees have equal opportunities to grow and succeed.

Looking ahead, Novartis remains a leader in the pharmaceutical industry, with a focus on developing innovative treatments for diseases that affect millions of people worldwide. The company's commitment to research and development, coupled with its dedication to corporate responsibility, positions Novartis as a trusted partner in healthcare. As Novartis continues to evolve and adapt to changing market dynamics, it will undoubtedly play a pivotal role in shaping the future of healthcare.

\n Weight: 1110g\n
Dimension: 285 x 285 x 23 (mm)\n
ISBN-13: 9781788169813\n
Edition number: Main\n


Correction of product information

If you notice any omissions or errors in the product information on this page, please use the correction request form below.

Correction Request Form

Product Review

You must be logged in to post a review